We found that in addition to CD33 (Siglec-3), Siglec-5/-14, -7, and -9, are differentially expressed on the CD16low and CD16high low-density subsets in both healthy, steady-state subjects, and cancer patients. The gene discussed is CD33; the disease is cancer.